A COMPREHENSION STUDY ON REGULATION OF HERBAL DRUGS IN USA, EUROPEAN UNION AND INDIA
Journal Title: International Journal of Drug Regulatory Affairs - Year 2017, Vol 5, Issue 4
Abstract
The present study reviews the regulations of herbal drugs in the EU, US and India and throws light upon issues related to their clinical trials. Herbal drugs have been used for a long time in different systems of health like Ayurveda, Yunani, Sidha and Homeopathy for treating number of diseases. It is a very difficult to perform clinical study on herbal drugs because these drugs are a complex combination of active ingredients. It is therefore difficult to identify the ingredient which is responsible for the therapeutic effect amongst various ingredients of herbal drugs. The standardization of herbal drugs is also a very difficult task. In spite of all these problems are existing public interest has increased towards herbal drugs in last 2-3 decades because of their long history of treating the disease safely. The laws and regulations for herbal drugs are different in different countries. The WHO has stated that each country should have a system to regulate herbal drugs in their territory. In the EU the committee on herbal medicinal products (HMPC) which part of the EMA was established under regulation (EC) No. 726/2004 and European directive 2004/24/EC in September, 2004. The main duty of HMPC is to evaluate and give authorization for herbal drugs on the basis of their safety and efficacy. In US herbs are classified as dietary supplements after the introduction of the Dietary Supplement Health and Education Act (DSHEA) in1994. In US herbal drugs are categorized into two types, first is OTC herbal drugs and drugs which required NDA approval. In India the Department of AYUSH has made guidelines for quality enhancement of herbal substances. The present study reviews the regulations of herbal drugs in the EU, US and India and throws light upon issues related to their clinical trials.
Authors and Affiliations
Budhwar Vikaas, Sunita Yadav, Manjusha Choudhary, Nitesh K
Keywords
Related Articles
- EP ID EP329065
- DOI 10.22270/ijdra.v5i4.205
- Views 123
- Downloads 0
PIC/S: TRAINING THE REGULATORS TO REGULATE cGMP COMPLIANCE
PIC/S is an international Organization for implementing cGMP standards in its member countries. The basic objective of PIC/S is to improve and standardize cGMP compliance in member countries. Their aim is to enhance GMP...
MEDICINES HARMONIZATION IN WEST AFRICAN ECONOMIC AND MONETARY UNION (WAEMU) COUNTRIES
With the blessing of WHO, the different regions of West Africa engaged in Pharmaceutical regulation harmonization processes on the continent. Indeed, In west Africa, WAEMU actions on the matter ended in the production of...
Regulation of Blood and Blood products in India, USA and EU
Blood and blood products are precious commodity which gives life to another person. Though we have immense discoveries and invention in science and technology, yet we cannot make blood hence, human blood has no substitut...
GENERIC MEDICINES REGULATION IN BRAZIL
The regulation of medicines in Brazil has proven to be one of the major concerns of government policies in recent decades. In order to improve access to quality medicines for the population, the National Drug Policy was...
FACTS ON DRUG REGULATIONS
The pharmaceutical products are very much driven by the drug regulation imposed by ministry of health in individual countries. The basic facts on regulations is that they are mandatory and noncompliant are punishable und...